The agreement between Diasorin and Roche has been signed: for 5 years, laboratories around the world will be able to take advantage of an integrated and automated system that will allow for better productivity and greater savings, through a strategic partnership to approach a new market by combining the excellence of the Italian Group of the world leader.
The collaboration, which is a rarity in the industry, is complemented by a comprehensive offering of test menus, predicting that the number of high-volume laboratories with the need to automate their diagnostic processes will grow steadily, exceeding 1.000 units within the next 5 years. Satisfied Carlo Rosa, Chief Executive Officer Diasorin: "The agreement with Roche represents a milestone that allows our Group to exploit a growing market opportunity with our Liaison XL system and related products".
Diasorin stock lost 0,6% in the mid-afternoon at Piazza Affari, at 33,50 euros per share.
